Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer

Saby George, Roberto Pili

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-naïve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.

Original languageEnglish (US)
Pages (from-to)65-68
Number of pages4
JournalCurrent Oncology Reports
Issue number2
StatePublished - Apr 2013
Externally publishedYes


  • Adenocarcinoma of prostate
  • Angiogenesis inhibitor
  • Castration resistant prostate cancer (CRPC)
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer'. Together they form a unique fingerprint.

Cite this